Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Velafermin (CuraGen).

Rajesh V Lalla1

  • 1Department of Oral Health and Diagnostic Sciences MC1605, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030-1605, USA. lalla@nso2.uchc.edu

Current Opinion in Investigational Drugs (London, England : 2000)
|November 30, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Randomized, double-blind, sham-controlled trial of an intraoral photobiomodulation device for oral mucositis and associated complications due to radiotherapy for head and neck cancer.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026
Same author

<i>Supportive Care in What</i>? Myths and Misconceptions That Prevent the Provision of Excellent Cancer Care.

JCO global oncology·2026
Same author

Oral dryness related symptoms in radiation-treated head and neck cancer patients: a pilot study of oral microbiome composition and function.

BMC microbiology·2026
Same author

The impact of medications on salivary flow and oral health-related quality of life in postradiation head and neck cancer patients: results of the OraRad study.

Oral surgery, oral medicine, oral pathology and oral radiology·2025
Same author

Mucoadhesive in situ forming Gels: Bridging Formulation design and physiological Realities.

International journal of pharmaceutics·2025
Same author

Prophylaxis, clinical management, and monitoring of datopotamab deruxtecan-associated oral mucositis/stomatitis.

The oncologist·2025
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

CuraGen is investigating velafermin for preventing and treating oral mucositis in cancer patients undergoing bone marrow transplant. Phase II trials were initiated in late 2004, with results anticipated in early 2006.

Area of Science:

  • Oncology
  • Pharmacology
  • Regenerative Medicine

Background:

  • Oral mucositis (OM) is a debilitating side effect of cancer therapy, significantly impacting patient quality of life.
  • Current treatments for OM offer limited efficacy, highlighting the need for novel therapeutic strategies.
  • Fibroblast growth factors play crucial roles in tissue repair and regeneration.

Purpose of the Study:

  • To evaluate the safety and efficacy of velafermin (CG-53135) for the prevention and treatment of oral mucositis.
  • To assess velafermin's potential in cancer patients undergoing bone marrow transplantation.

Main Methods:

  • Velafermin, a recombinant human fibroblast growth factor-20, is administered intravenously.
  • Phase II clinical trials were initiated to investigate velafermin's therapeutic potential.

Related Experiment Videos

  • The study population includes cancer patients undergoing bone marrow transplant.

    • Main Results:

    • Phase II trials for OM prevention in bone marrow transplant patients were initiated by December 2004.
    • CuraGen announced in September 2005 that study results would be available in Q1 2006.

    Conclusions:

    • Velafermin shows promise as a potential therapeutic agent for oral mucositis.
    • Further clinical evaluation is warranted to establish velafermin's role in OM management.